A Mayo Clinic BioPharma Diagnostics engagement offers partners access to Mayo Clinic Laboratories’ robust library of hematology evaluations. Our extensive testing menu features diagnostic, prognostic, and monitoring assays across the spectrum of hematological disorders. From state-of-the-art MALDI-TOF mass spectrometry (MASS-FIX) evaluations for the detection of monoclonal protein disorders, to comprehensive fluorescence in-situ hybridization (FISH) panels for personalized insights on lymphoma and myeloid neoplasms, our assays offer partners the tools needed to expediate clinical trial and drug development solutions.
Mayo Clinic Laboratories’ hematology testing laboratories are led by board-certified hematologists and hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders. Our expert-backed tests are designed to improve outcomes, increase efficiency, and decrease costs.
A Mayo Clinic BioPharma Diagnostics collaboration enables access to the hematological disease testing capabilities of Mayo Clinic Laboratories, including:
Learn more about clinically approved hematology testing from Mayo Clinic Laboratories.
Mayo Clinic Laboratories has developed an assay that offers enhanced detection of the NPM1 genetic mutation that is present in about 30% of patients with acute myeloid leukemia, or AML.
Yi Lin, M.D., Ph.D., associate professor of medicine at Mayo Clinic and medical director for the Cellular Therapy Program, led a survey to investigate the scope of this problem, which has not been covered in literature thus far. The findings were published as an abstract at the recent annual meeting of the American Society of Clinical Oncology.